GlassScriptPhysician profile
Fernando J Manalac
NPI 1316170350
$14,931.81
in general payments reported to CMS, 2019-2025
8 companies · $6,861 in 2025
The $6,861 reported for 2025 was more than what 98% of Sports Medicine (Internal Medicine) providers received nationally (typical 2025 total: $99.49).
See the full distribution for Sports Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2022: $60.82 · 2023: $409 · 2024: $7,414 · 2025: $6,861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Travel and Lodging: $2,612 · Food and Beverage: $1,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,786.32 |
| Travel and Lodging | $2,611.70 |
| Food and Beverage | $1,286.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $13,213.30 | 2024-2025 | Monovisc |
| Depuy Synthes Sales INC. | $869.78 | 2022-2025 | Monovisc, Orthovisc |
| Arthrex, INC. | $501.35 | 2019-2024 | |
| Pacira Therapeutics, INC. | $156.59 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $95.61 | 2023-2025 | Iovera, Zilretta, Exparel |
| Bioventus LLC | $53.49 | 2022-2025 | Durolane, Xcell |
| Southern Edge Orthopaedics, INC. | $23.88 | 2025 | |
| Mindray Ds USA, INC. | $17.81 | 2025 | Te7 Max, Te X |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Manalac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.